25654-31-3

Cannabigerol (CRM) (Item No. 20164) is a certified reference material categorized as a phytocannabinoid. This product is intended for research and forensic applications.

Cannabigerol is a partial agonist of CB2 and CB1 receptors (Ki values are 337 and 440 nM respectively). Cannabigerol also exhibits α2-adrenoceptor agonist activity (EC50 = 0.2 nM in mouse brain membra nes).

ChEBI: A natural product found in Cannabis sativa and Helichrysum species.

Cannabigerol (CBG) works to fight inflammation, pain, nausea and works to slow the proliferation of cancer cells. Research has shown it also significantly reduces intraocular eye pressure caused by glaucoma. Strains high in CBG will be beneficial treating conditions such as inflammatory bowel disease, Crohn's disease, and cancer.

Analog of cannabidiol with similar pharmacological properties.

Cannabigerol shares a similar mechanism of action with the cannabinoid cannabidiol, since it binds itself weakly to CB1R and CB2R and, in addition to blocking CB1R, antagonizes 5-HT1A receptor, activates alpha (2) adrenoceptors, and is a modulator of endocannabinoid signaling. CBG acts as a strong α2-adrenoceptor agonist (EC50?=?0.2?nM), while it is only a moderate 5-HT1AR competitive antagonist, and at high concentrations (10?μM), it antagonizes [35S] guanosine 5′-O-[gamma-thio]triphosphate (GTPγS) binding in mouse brain membranes stimulated with AEA or CP-55940[1].

TRPV | 5-HT Receptor | ROS | NOS | PPAR | IGF-1R | Antifection

Store at -20°C

[1] Fabrizio Calapai. “Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives.” Evidence-based Complementary and Alternative Medicine (2022): 3336516.